ArticleSubstance abuse2019
Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?
Article in Substance abuse, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 72 citations in OpenAlex.
- Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse.Addiction (Abingdon, England) · 2022Trial
- A mixed-method exploratory assessment of provider-based stigma of opioid use disorder (OUD) and support for medications for opioid use disorder (MOUD) in carceral settings.Harm reduction journal · 2025Article
- Medication for opioid use disorder service delivery in carceral facilities: update and summary report.Health & justice · 2025Review
- Client and program-level factors associated with planned use of medications for opioid use disorder in specialty substance use treatment programs: Evidence from linked administrative data and survey data.Journal of substance use and addiction treatment · 2025Article
- "Yeah, this is not going to work for me"-The impact of federal policy restrictions on methadone continuation upon release from jail or prison.Journal of substance use and addiction treatment · 2025Article
- Dynamics of prescribing and accessing medications for opioid use disorder: a community-based systems analysis.Addiction research & theory · 2024Article
- Extended-release buprenorphine induction in opioid non-tolerant incarcerated individuals.Drug and alcohol dependence reports · 2024Article
- Harm Reduction and Treatment Among People at High Risk of Overdose.JAMA network open · 2024Article
- Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.Journal of substance use and addiction treatment · 2024Article
- Patient perceptions of and experiences with stigma using telehealth for opioid use disorder treatment: a qualitative analysis.Harm reduction journal · 2024Article
- Article
- Medicaid Managed Care Prior Authorization For Buprenorphine Tied To State Partisanship And Health Plan Profit Status, 2018.Health affairs (Project Hope) · 2024Article
- Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts.The International journal on drug policy · 2023Article
- Supervised on-site dosing in injectable opioid agonist treatment-considering the patient perspective. Findings from a cross-sectional interview study in two German cities.Harm reduction journal · 2023Article
- Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach.Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing · 2023Article
- Between Care and Control: Examining Surveillance Practices in Harm Reduction.Contemporary drug problems · 2023Article
- Scope of, Motivations for, and Outcomes Associated with Buprenorphine Diversion in the United States: A Scoping Review.Substance use & misuse · 2023Article
- Characterization of Unintentional Deaths Among Buprenorphine Users.Journal of studies on alcohol and drugs · 2023Article
- A Better Life: Factors that Help and Hinder Entry and Retention in MAT from the Perspective of People in Recovery.Journal of Appalachian health · 2023Article
- Toward evaluation of disseminated effects of medications for opioid use disorder within provider-based clusters using routinely-collected health data.Statistics in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Buprenorphine is considered one of the most effective treatments for opioid use disorder and significantly reduces risk of overdose death. However, concerns about its diversion and misuse have often taken center stage in public discourse and in the design of practices and policies regarding its use. This has been to the detriment of many vulnerable patient populations, especially those involved in the criminal justice system. Policies that restrict access to buprenorphine in criminal justice and other settings due to concerns of diversion do not accurately reflect the relative risks and safety profile associated with it, creating unnecessary barriers that drive an illicit market of this much-needed medication. Although proper regulation of all controlled medications should be a priority, in most instances the benefits of buprenorphine highly outweigh its risks. In the midst of a national crisis, efforts should be focused on expanding, and not restricting, access to this lifesaving treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.